Home
    • Plans Blog Contact
    Aktis Oncology, Inc. logo

    Aktis Oncology, Inc.

    AKTS
    Last price US$23.89
    Market cap US$1.5b
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Propanc Biopharma, Inc.PPCB Industry peer Ascentage Pharma Group InternationalAAPG Industry peer Aardvark Therapeutics, Inc.AARD Industry peer Shoulder Innovations, Inc.SI Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Aktis Oncology, Inc. Overview

    Industry: Biotechnology: Pharmaceutical Preparations

    Sector: Health Care

    Aktis Oncology is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. We see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope. To ensure patient demand is reliably met, we are also establishing efficient end-to-end supply, with a combination of critical internal capabilities paired with established external vendors. Through these efforts, we seek to maximize clinical utility across multiple indications in multiple tumor types, and to expand the commercial uptake of radiopharmaceuticals beyond the traditional nuclear medicine setting and into the more expansive clinical oncology setting. Aktis Oncology is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. We see a significant opportunity to broaden the cancer patient populatio Read More

    Newly listed company coverage

    Verified company profile, price history, and SEC registration source are available.

    Review the SEC registration filing

    Mavefund brings filings, fundamentals, valuation, price history and news for Aktis Oncology, Inc. into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 11, 2026

    Quarterly result summary

    Revenue was $3.2M (+129% YoY). Net loss was -$18.3M (from $15M). R&D expense was $20M.

    Revenue $3.2M +129% YoY
    Net loss -$18.3M from $15M
    R&D expense $20M reported
    G&A expense $5.9M reported

    What changed

    • Revenue +129% YoY to $3.2M.
    • Net loss was -$18.3M (from $15M).

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings material Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K May 11, 2026 SEC filing 10-Q May 11, 2026 Earnings release Earnings release Mar 30, 2026 SEC filing 10-K Mar 30, 2026 SEC filing 8-K Mar 30, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Aktis Oncology, Inc. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Propanc Biopharma, Inc. Shoulder Innovations, Inc.
    In Biotechnology: Pharmaceutical Preparations industry , Propanc Biopharma, Inc. , Ascentage Pharma Group International , Aardvark Therapeutics, Inc. are companies with high ratings.

    Return on Equity

    Score 0.00/5
    Aktis Oncology, Inc. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Propanc Biopharma, Inc. Shoulder Innovations, Inc.
    Aktis Oncolo... AKTS US$1.5b
    Propanc Biop... PPCB US$35.6m
    Shoulder Inn... SI US$637.2m

    Net Margin

    Score 0.00/5
    Aktis Oncology, Inc. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Propanc Biopharma, Inc. Shoulder Innovations, Inc.
    Aktis Oncolo... AKTS US$1.5b
    Propanc Biop... PPCB US$35.6m
    Shoulder Inn... SI US$637.2m

    Share Buyback

    In Biotechnology: Pharmaceutical Preparations industry , Propanc Biopharma, Inc. , Ascentage Pharma Group International , Aardvark Therapeutics, Inc. are companies with high ratings.

    Leverage

    Score 1.00/5
    Aktis Oncology, Inc. registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Propanc Biopharma, Inc. Shoulder Innovations, Inc. have achieved high scores.
    Aktis Oncolo... AKTS US$1.5b
    Propanc Biop... PPCB US$35.6m
    Shoulder Inn... SI US$637.2m

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Aktis Oncology, Inc. logo

    Aktis Oncology, Inc.

    US$23.89

    US$1.5b

    -14.31%

    N/A